ACR 2022 Tweet by David Liew

Tweet
David Liew @drdavidliew Nov 13, 2022
View on
Tofacitinib in new-onset PMR:
Nice mechanistic data - all the right things line up - leading to promising proof-of-concept study (EAST PMR)

Plenty to tease apart here but real promise to explore in bigger studies

ABST1107 #ACR22 @RheumNow
Image from David Liew’s tweet

Related Content

Article General Rheumatology

EBR Journal Club: Secukinumab in Polymyalgia Rheumatica (REPLENISH)

Michael Putman, MD, MSCI Oct 22, 2026
This edition: REPLENISH (secukinumab in polymyalgia rheumatica). The EBR Journal Club Companion applies my adapted version of the JAMA approach to critical appraisal to an important RCT in rheumatology. Each review covers four domains: Does this apply to my patients? What is the risk of bias? How great are the benefits and harms? And what didn’t they show me?
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

Topics

×